Special Issue "Photodynamic Therapy: Applications against Microorganisms"
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 7843
Interests: phage therapy; antimicrobial photodynamic therapy; alternative approaches to antibiotics
Special Issues, Collections and Topics in MDPI journals
Special Issue in Microorganisms: Bacteriophage Treatment as an Alternative Technology to Inactivate Pathogenic Bacteria: A Generalized Worldwide Growing Acceptance
Special Issue in Antibiotics: 10th Anniversary of Antibiotics—Recent Advances in Bacteriophage Therapy
Special Issue in Antibiotics: Phage Therapy to Control Pathogenic Bacteria, 2nd Edition
The increasing number of drug-resistant microbial infections is an emerging global health crisis that is driving a growing demand for alternative therapies to conventional antimicrobials. Antimicrobial photodynamic therapy (aPDT) is a likely approach to deal with this devastating scenario of drug resistance, but with a few exceptions (e.g., using 5-aminolevulinic acid and hematoporphyrin derivatives as aPDT mediators), no protocol currently holds a marketing authorisation that would allow its free use in human medicine. Although compassionate treatments permit the use of unapproved medicines to treat patients with no more approved therapeutic options, aPDT has not yet been used with this option. Moreover, as drug resistance is not only a problem of human medicine, occurring also in animal and environmental sectors, it is important to extend the aPDT efforts to other areas such as veterinary medicine, aquaculture, agriculture and food industry.
As antimicrobial resistance continues to increase, there is much to be done in order to streamline aPDT efforts, particularly in terms of developing efficient protocols and simple synthetic strategies able to afford effective, inexpensive and safe photosensitizers. It is expected that this Special Issue can motivate physicians and researchers to respond to the current underutilization of aPDT in human, animal and environmental sectors in order to develop effective and safe therapeutics and applications.Prof. Dr. Adelaide Almeida
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.